COMPANY SUMMARY
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
Financial Summary
| Share Statistics |
FTRE |
Industry Median |
Percentile (All Stocks) |
| Market Cap (Mil) |
$1,955.3 |
$3,712.8 |
54% |
|
| Shares Out (Mil) |
94.8 |
101.8 |
61% |
|
| Institutional Ownership |
98.9% |
88.5% |
83% |
|
| Float (Mil) |
94.0 |
73.5 |
59% |
|
| Beta |
1.95 |
1.19 |
91% |
|
| Avg Daily Volume (000s) |
1,635 |
906 |
78% |
|
Price Change (52-week) |
114.4% |
86.3% |
95% |
|
| Growth |
FTRE |
Industry Median |
Percentile (All Stocks) |
| Sales (5yr) |
1.1% |
7.8% |
21% |
|
| Net Income (5yr) |
(22.4%) |
(11.2%) |
18% |
|
| EPS (5yr) |
na |
2.5% |
na |
|
| Dividends (5yr) |
0.0% |
0.0% |
0% |
|
| Cash Flow (5yr) |
na |
(15.0%) |
na |
|
| Estimates |
Qtrly |
Current Fiscal Year |
Next Fiscal Year |
| # of Estimates |
12 |
12 |
13 |
| Current EPS |
$0.217 |
$0.844 |
$1.145 |
| Month Ago EPS |
$0.211 |
$0.840 |
$1.139 |
| # Rev Up |
1 |
0 |
0 |
| # Rev Down |
0 |
0 |
0 |
| Three Months Ago EPS |
$0.213 |
$0.807 |
$1.077 |
| Year/Year Chg |
(256.1%) |
(107.8%) |
(112.9%) |
| Financials |
FTRE |
Industry Median |
Percentile (All Stocks) |
| Sales (TTM) (Mil) |
$2,677 |
$800 |
64% |
|
| Net Income (TTM) (Mil) |
($85) |
($32) |
12% |
|
| EPS (TTM) |
($0.915) |
($0.300) |
22% |
|
| Operating Cash Flow (TTM) (Mil) |
$228 |
$47 |
61% |
|
| Net Cash Flow (TTM) (Mil) |
na |
$5 |
na |
|
| Long-Term Debt (Q1) (Mil) |
$1,092 |
$230 |
67% |
|
| Enterprise Value (Q1) (Mil) |
$2,853 |
$3,714 |
54% |
|
| Valuation |
FTRE |
Industry Median |
Percentile (All Stocks) |
| P/B |
3.73 |
3.83 |
73% |
|
| P/E |
na |
39.2 |
na |
|
| Dividend Yield |
0.0% |
0.0% |
0% |
|
| PEG (5yr hist) |
na |
6.0 |
na |
|
| Ratios |
FTRE |
Industry Median |
Percentile (All Stocks) |
| Gross Margin |
19.3% |
47.5% |
20% |
|
| Net Margin |
(3.2%) |
(6.0%) |
27% |
|
| ROA |
(3.1%) |
(4.8%) |
32% |
|
| ROE |
(15.3%) |
(7.9%) |
25% |
|
| Liabilities to Assets |
80.7% |
41.1% |
76% |
|
| F-Score |
4 |
5 |
33% |
|
Passing Stock Screens
As of 10/7/2026, from a list of 60 stock screening strategies,
FTRE meetings the criteria of 4 screen:
Stock Screen
GURU STRATEGY
Kirkpatrick Bargain Screen
Factors: Value, Momentum
Investing model outlined in Charles Kirkpatrick's book, Beat the Market: Invest by Knowing What Stocks to Buy and What Stocks to Sell.
GURU STRATEGY
O'Shaughnessy: Growth Screen II
Factors: Value, Momentum
O'Shaughnessy tries to predict the future using historical long-term trends.
GURU STRATEGY
O'Shaughnessy: Small Cap Growth & Value Screen
Factors: Value, Size, Momentum
O'Shaughnessy tries to predict the future using historical long-term trends.
GURU STRATEGY
Driehaus Revised Screen
Factors: Size, Momentum, Growth, Earnings Estimates
Revisiting the approach of the "father of momentum investing," Richard Driehaus, that seeks out companies with accelerating earnings growth, rising earnings estimates and meaningful positive earnings surprises.